Psychedelic Stocks

2020-09-04 PSW Editor

Aion Therapeutic Inc. has filed several plant-based patents with the USPTO.

2020-09-03 PSW Editor

Another private player in the psychedelics industry moves to go public. Prospectus available on SEDAR.

2020-09-03 PSW Editor

Numinus seeks to raise CAD$4.0 million at an offering price of CAD$0.25 per unit.

2020-08-31 Jeff Nielson

A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.

2020-08-28 PSW Editor

Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.

2020-08-27 Jeff Nielson

As the Renaissance for psychedelic drugs progresses, we see these substances acquiring mainstream status in various ways.

2020-08-27 PSW Editor

Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.

2020-08-26 PSW Editor

Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.

2020-08-25 PSW Editor

MindMed is utilizing MDMA with LSD, to endeavour to reduce side effects of LSD-assisted therapy.

2020-08-24 Jeff Nielson

Wall Street and Silicon Valley investors recently piled into a $30-million psychedelics fund-raising initiative.

2020-08-24 PSW Editor

Field Trip Psychedelics completes its qualifying transaction and definitive agreement with RTO partner.

2020-08-21 PSW Editor

Wuhan General (soon to be M2Bio Sciences) has released a corporate update on its psychedelics and cannabis operations.